Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLM Apollomics	$4.16 -33.3%	$6.04	$4.09 ▼ $35.98	$4.57M	0.92	23,690 shs	95,468 shs
NKGN NKGen Biotech	$0.13 -8.6%	$0.21	$0.10 ▼ $0.96	$5.96M	1.19	1.58 million shs	851 shs
ONCO Onconetix	$2.99 +1.5%	$3.71	$2.61 ▼ $552.50	$4.61M	3.37	374,010 shs	12,796 shs
PPBT Purple Biotech	$2.23 +0.5%	$2.36	$2.00 ▼ $13.95	$5.78M	0.49	86,048 shs	28,201 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLM Apollomics	+2.81%	+15.58%	-2.20%	+0.16%	-53.58%
NKGN NKGen Biotech	0.00%	+9.43%	-23.68%	-50.00%	-80.65%
ONCO Onconetix	-4.85%	+7.69%	-20.75%	-56.76%	-99.42%
PPBT Purple Biotech	-1.77%	+0.05%	-1.33%	-7.11%	+221,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLM Apollomics	0.3862 of 5 stars	0.0	3.0	0.0	0.0	3.3	0.0	0.0
NKGN NKGen Biotech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONCO Onconetix	1.1056 of 5 stars	0.0	4.0	0.0	0.0	3.8	0.0	0.6
PPBT Purple Biotech	1.8439 of 5 stars	3.5	2.0	0.0	0.0	2.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLM Apollomics	0.00	N/A	N/A	N/A
NKGN NKGen Biotech	0.00	N/A	N/A	N/A
ONCO Onconetix	0.00	N/A	N/A	N/A
PPBT Purple Biotech	3.00	Buy	$33.00	1,379.82% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLM Apollomics	$1.49M	3.07	N/A	N/A	$4.48 per share	0.93
NKGN NKGen Biotech	N/A	N/A	N/A	N/A	($2.68) per share	N/A
ONCO Onconetix	$1.33M	3.48	N/A	N/A	$3.82 per share	0.78
PPBT Purple Biotech	N/A	N/A	N/A	N/A	$12.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLM Apollomics	-$53.86M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
NKGN NKGen Biotech	-$82.94M	-$2.45	N/A	∞	N/A	N/A	N/A	-479.36%	N/A
ONCO Onconetix	-$58.69M	N/A	0.00	∞	N/A	-3,327.03%	-192.74%	-89.55%	N/A
PPBT Purple Biotech	-$7.24M	-$0.42	N/A	N/A	N/A	N/A	-14.00%	-12.52%	N/A

Latest ONCO, NKGN, APLM, and PPBT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ONCO Onconetix	N/A	-$4.05	N/A	-$4.76	N/A	$0.11 million
8/6/2025	Q2 2025	PPBT Purple Biotech	-$0.21	-$0.40	-$0.19	-$0.40	N/A	N/A
6/12/2025	Q1 2025	ONCO Onconetix	N/A	$21.25	N/A	-$0.53	N/A	$0.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLM Apollomics	N/A	N/A	N/A	N/A	N/A
NKGN NKGen Biotech	N/A	N/A	N/A	N/A	N/A
ONCO Onconetix	N/A	N/A	N/A	N/A	N/A
PPBT Purple Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLM Apollomics	N/A	1.39	1.39
NKGN NKGen Biotech	N/A	0.02	0.02
ONCO Onconetix	N/A	0.07	0.06
PPBT Purple Biotech	N/A	2.88	2.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLM Apollomics	19.13%
NKGN NKGen Biotech	76.17%
ONCO Onconetix	23.89%
PPBT Purple Biotech	9.64%

Insider Ownership

Company	Insider Ownership
APLM Apollomics	N/A
NKGN NKGen Biotech	10.36%
ONCO Onconetix	3.10%
PPBT Purple Biotech	2.98%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLM Apollomics	45	1.10 million	N/A	Not Optionable
NKGN NKGen Biotech	N/A	44.95 million	40.29 million	Not Optionable
ONCO Onconetix	12	1.55 million	1.50 million	N/A
PPBT Purple Biotech	20	2.59 million	2.51 million	Optionable

ONCO, NKGN, APLM, and PPBT Headlines

Recent News About These Companies

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

August 27 at 7:00 AM | globenewswire.com

Purple Biotech Reports Second Quarter 2025 Financial Results

August 6, 2025 | globenewswire.com

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

July 23, 2025 | globenewswire.com

Purple Biotech Stock Price History - Investing.com

July 8, 2025 | investing.com

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

June 23, 2025 | globenewswire.com

Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer

June 17, 2025 | finance.yahoo.com

Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform

June 4, 2025 | finance.yahoo.com

H.C. Wainwright Raises Purple Biotech (PPBT) Price Target, Reiterates Buy Rating

June 1, 2025 | msn.com

Purple Biotech Ltd.: Purple Biotech Reports First Quarter 2025 Financial Results

May 21, 2025 | finanznachrichten.de

Purple Biotech Reports First Quarter 2025 Financial Results

May 21, 2025 | globenewswire.com

Purple Biotech Appoints Shai Lankry as Chief Financial Officer to Drive Strategic Growth and Financial Excellence

May 13, 2025 | nasdaq.com

Purple Biotech appoints Shai Lankry as new CFO

May 13, 2025 | investing.com

Purple Biotech Ltd.: Purple Biotech Appoints Shai Lankry as Chief Financial Officer

May 12, 2025 | finanznachrichten.de

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

May 12, 2025 | globenewswire.com

Purple Biotech Unveils Promising Phase 2 Results for CM24 in Pancreatic Cancer

April 30, 2025 | tipranks.com

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

April 28, 2025 | globenewswire.com

Purple Biotech announces publication of study on potential of NT219

April 17, 2025 | markets.businessinsider.com

Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting

March 28, 2025 | finance.yahoo.com

Purple Biotech Unveils Updated Oncology Pipeline Progress

March 18, 2025 | tipranks.com

Purple Biotech Reports Positive Clinical Trial Results for CM24 and NT219, Advancing to Phase 2 Studies

March 12, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO, NKGN, APLM, and PPBT Company Descriptions

Apollomics NASDAQ:APLM

$4.16 -2.08 (-33.31%)

As of 03:51 PM Eastern

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

NKGen Biotech NYSE:NKGN

$0.13 -0.01 (-8.62%)

As of 12:37 PM Eastern

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

Onconetix NASDAQ:ONCO

$2.98 +0.05 (+1.53%)

As of 03:47 PM Eastern

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Purple Biotech NASDAQ:PPBT

$2.23 +0.01 (+0.45%)

As of 03:44 PM Eastern

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time